Shandong Xinhua Pharma Sustainability Profile
Shandong Xinhua Pharmaceutical Company Limited, commonly referred to as Xinhua Pharma, is a prominent player in the pharmaceutical industry, headquartered in Shandong, China. Established in 1996, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong focus on research and development, Xinhua Pharma has carved out a niche in the production of high-quality generic medications and innovative therapies. The company is recognised for its commitment to quality and compliance with international standards, which has bolstered its market position both domestically and globally. Notable achievements include various certifications and partnerships that enhance its reputation as a reliable supplier in the pharmaceutical sector.
DitchCarbon Score
How does Shandong Xinhua Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Xinhua Pharma's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shandong Xinhua Pharma's reported carbon emissions
In 2023, Shandong Xinhua Pharmaceutical Company Limited reported total carbon emissions of approximately 260,643,000 kg CO2e, comprising 18,956,000 kg CO2e from Scope 1 and 241,687,000 kg CO2e from Scope 2 emissions. This represents a slight increase from 2022, where total emissions were about 258,468,000 kg CO2e, with Scope 1 emissions at 14,098,000 kg CO2e and Scope 2 emissions at 244,370,000 kg CO2e. In 2021, the company recorded total emissions of around 250,960,000 kg CO2e, with Scope 1 at 23,065,000 kg CO2e and Scope 2 at 227,895,000 kg CO2e. Despite these figures, Shandong Xinhua Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The company has not reported any Scope 3 emissions, indicating a focus primarily on direct and indirect emissions from their operations. There are no climate pledges or SBTi (Science Based Targets initiative) commitments noted in their disclosures. Overall, while Shandong Xinhua Pharma has made strides in tracking and reporting emissions, the absence of reduction targets suggests an opportunity for further commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Shandong Xinhua Pharma's Industry?
How Carbon Intensive is Shandong Xinhua Pharma's Location?
Shandong Xinhua Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shandong Xinhua Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
